M Iorfida
Overview
Explore the profile of M Iorfida including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
231
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Munzone E, Pagan E, Bagnardi V, Montagna E, Cancello G, Dellapasqua S, et al.
ESMO Open
. 2021 Dec;
6(6):100332.
PMID: 34864350
Background: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and endocrine therapy (ET) deeply transformed the treatment landscape of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer. Randomized clinical trials...
2.
Montagna E, Bellerba F, Sangalli C, Gandini S, Cancello G, Trillo Aliaga P, et al.
Eur J Surg Oncol
. 2021 Jun;
47(10):2694-2695.
PMID: 34116901
No abstract available.
3.
Montagna E, Pagan E, Bagnardi V, Colleoni M, Cancello G, Munzone E, et al.
Breast Cancer Res Treat
. 2020 Sep;
184(3):783-795.
PMID: 32929568
Purpose: The development of the adjuvant therapy requires that clinicians and patients should discuss the magnitude of benefit of treatment for individual patient, estimating the pros and cons and the...
4.
Galimberti V, Ribeiro Fontana S, Maisonneuve P, Steccanella F, Vento A, Intra M, et al.
Eur J Surg Oncol
. 2016 Jan;
42(3):361-8.
PMID: 26746091
Purpose: It is controversial whether sentinel node biopsy (SNB) without axillary dissection (AD) should be performed in cN1/2 breast cancer patients who become cN0 after neoadjuvant treatment, since the false...
5.
Montagna E, Peccatori F, Petralia G, Tomasi Cont N, Iorfida M, Colleoni M
Breast
. 2014 Feb;
23(3):295-6.
PMID: 24529906
No abstract available.
6.
Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua M, Pruneri G, et al.
Ann Oncol
. 2012 Oct;
24(3):661-8.
PMID: 23022996
Background: The immunohistochemical (IHC) evaluation of estrogen receptor (ER), progesterone receptor (PgR), Ki-67 and HER2 is considered a surrogate means for identifying the molecular subtypes of breast cancer with different...
7.
Iorfida M, Dellapasqua S, Bagnardi V, Cardillo A, Rotmensz N, Mastropasqua M, et al.
Ann Oncol
. 2012 Mar;
23(5):1371-1372.
PMID: 22412042
No abstract available.
8.
Colleoni M, Rotmensz N, Maisonneuve P, Mastropasqua M, Luini A, Veronesi P, et al.
Ann Oncol
. 2011 Nov;
23(6):1428-36.
PMID: 22039080
Background: The identification of special types of breast cancer might be of value in assessing prognosis and predicting response to therapy. Methods: A total of 7372 consecutive patients with immunohistochemically...
9.
Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua M, Pruneri G, et al.
Breast Cancer Res Treat
. 2011 Apr;
127(3):713-20.
PMID: 21452022
Knowledge is limited about prognostic significance of breast cancer subtypes among women with small invasive node-negative breast tumours. We explored patterns of recurrence in 1691 women with pT1mic/T1a/T1b, pN0 and...
10.
Caristi N, Maisano R, Iorfida M, Scimone A, Lupo G, Buda C, et al.
J Chemother
. 2008 Jul;
20(3):368-73.
PMID: 18606594
Hormone-refractory prostate cancer (HRPC) is a rapidly progressive disease which produces considerable morbidity and involves mostly men over 70, often comorbid and with poor tolerance to chemotherapy. Low-toxicity chemotherapy is...